0001140361-24-011170.txt : 20240304
0001140361-24-011170.hdr.sgml : 20240304
20240304185422
ACCESSION NUMBER: 0001140361-24-011170
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240229
FILED AS OF DATE: 20240304
DATE AS OF CHANGE: 20240304
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Militello John
CENTRAL INDEX KEY: 0001662170
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36829
FILM NUMBER: 24717384
MAIL ADDRESS:
STREET 1: C/O IMMUNE PHARMACEUTICALS INC.
STREET 2: 430 EAST 29TH STREET, SUITE 940
CITY: NEW YORK
STATE: NY
ZIP: 10016
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ROCKET PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001281895
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 350 FIFTH AVENUE
STREET 2: SUITE 7530
CITY: NEW YORK
STATE: NY
ZIP: 10118
BUSINESS PHONE: 646-440-9100
MAIL ADDRESS:
STREET 1: 350 FIFTH AVENUE
STREET 2: SUITE 7530
CITY: NEW YORK
STATE: NY
ZIP: 10118
FORMER COMPANY:
FORMER CONFORMED NAME: INOTEK PHARMACEUTICALS CORP
DATE OF NAME CHANGE: 20040226
4
1
form4.xml
FORM 4
X0508
4
2024-02-29
0001281895
ROCKET PHARMACEUTICALS, INC.
RCKT
0001662170
Militello John
C/O ROCKET PHARMACEUTICALS, INC.
9 CEDARBROOK DRIVE
CRANBURY
NJ
08512
true
See Remarks
false
Common Stock
2024-02-29
4
M
0
10000
12.55
A
31517
D
Common Stock
2024-02-29
4
S
0
10000
29.845
D
21517
D
Stock Option (Right to Buy)
12.55
2024-02-29
4
M
0
10000
12.55
D
2028-01-28
Common Stock
10000
0
D
Represents shares received upon exercise of a Stock Option.
Represents a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.78 to $29.91. The Reporting Person has provided the issuer and will provide any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock, one-third of which became fully vested and exercisable on January 8, 2019, with the remaining two-thirds vesting in equal quarterly installments over the following two years.
VP, Principal Accounting Officer and Interim Principal Financial Officer
/s/ Martin Wilson, as attorney-in-fact for John Militello
2024-03-04